TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced colorectal cancer failed from all standard chemotherapy~  * History of refractoriness from chemotherapy including 5-FU, Oxaliplatin, Irinotecan~ * Oral 5-FU agents are included standard chemotherapy~ * Targeted agents such as cetuximab or bevacizumab are not included in inclusion criteria~* Patient must have willingness and ability to comply with the study protocol including visiting hospital for test and treatment during trial~* ECOG performance status 0\~2~* Measurable lesion (RECIST 1.1) must exist~* Expected survival should be more than 3 months from first dose of pemetrexed~* Adequate organ function as defined as below estimated 28 days before first doe of pemetrexed:~Exclusion Criteria:~* Poor performance status (ECOG PS ≥ 3)~* Patient can not take folic acid or Vitamin B12.~* History of previous treatment with pemetrexed~* History of malignant disease, except: non-melanoma skin cancer that properly treated, cured uterine cervical cancer or other solid tumor without evidence of recurrence within 5 years~* Patient can not swallow oral pills.~* Treatment with medication of clinical trial within 14 days (or longer duration according to specific agents)~* Systemic chemotherapy or radiation (except palliative purpose) within 3 weeks (or longer duration according to specific agents)~* Toxicity from previous treatment as CTCAE grade \> 1, except alopecia~* bowel obstruction or CTCAE grade 3/4 upper GI bleeding before 4 weeks~* QTc prolongation (QTc \> 480msec) at resting is documented more than twice within 24 hours or family history of QT prolongation syndrome

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed+Tarceva (Type: EXPERIMENTAL): Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dialysis patients with hyperphosphataemia (≥ 1.94 mmol/L; ≥ 6.0 mg/dL)~* Stable dose of phosphate binder~* Written informed consent~Exclusion Criteria:~* Hyper/hypo calcemia; hyper intact parathyroid hormone (iPTH)~* Other significant medical conditions~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PA21 (2.5 g tablet) (Type: EXPERIMENTAL): None
- Sevelamer carbonate (Type: ACTIVE_COMPARATOR): None
- PA21-1 (1.25 g tablet) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of an Oral Contraceptive

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Women~* Age 18-45~* At risk for pregnancy~* History of regular cycles~Exclusion Criteria:~* Contraindications for use of hormonal contraception~* Conditions which affect the absorption or metabolism of steroid hormones~* BMI \> 35

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- study drug (Type: EXPERIMENTAL): Norethindrone/Ethinyl Estradiol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin.~* Fasting LDL-C \> 70 mg/dL and triglyceride \<=400 mg/dL.~* High or very high risk of incurring a cardiovascular event.~* Heterozygous familial hypercholesterolemia.~Exclusion Criteria:~* Pregnant or breastfeeding females.~* Cardiovascular or cerebrovascular event of procedures during the past 30 days.~* Congestive heart failure NYHA class IV.~* Poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615;RN316) (Type: EXPERIMENTAL): Bococizumab (PF-04950615;RN316)
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 12 months since diagnosis~* Insulin naive subjects~* OAD treatment for at least 4 months alone or combined with no more than two OADs~* Body mass index (BMI) below 35.0 kg/m2~* HbA1c between 7.5-10.0%~* Able and willing to use twice a day injections for the entire trial period~Exclusion Criteria:~* Current or previous treatment with thiazolidiones within the last 6 months~* OAD treatment with three or more OADs within the last 6 months~* Acute insulin treatment for longer than 7 days in a row within the last 6 months~* Secondary diabetes~* Known maturity onset of diabetes of young (MODY)~* Known or suspected allergy to trial product or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hoarding Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants must be between the ages of 60 - 85 years old and meet clinical criteria for Compulsive Hoarding (CH) developed by the Steketee and Frost (2000) research group. These criteria include:~* significant amount of clutter in active living spaces~* the urge to collect, buy, or acquire things~* an extreme reluctance to part with items~* clutter accumulation that causes distress or interferes with functioning~* symptom duration of at least 6 months~* the reluctance to part with items is not accounted for by other psychiatric conditions.~To be enrolled, patients must have:~* a score of 20 or greater on the University of California, Los Angeles Hoarding Severity Scale (UHSS)~* 40 or greater on the Savings Inventory-Revised (SI-R)~* severity rating of 4 or higher on the Anxiety Disorders Interview Schedule (ADIS-IV) rating scales for clutter and difficulty discarding~* and diagnosis confirmed at a consensus conference including at least two licensed professionals with expertise in CH (myself and at least one mentor).~Exclusion Criteria:~* Individuals with moderate to severe cognitive deficits (scores below 23 on the MMSE) will be excluded.~* Prospective participants must not have active substance abuse problems.~* Participants will also be excluded if they are currently in other forms of psychotherapy.~* Participants must have no change in any psychotropic medications for at least three months prior to the initial assessment.~* Patients with current psychosis or mania will be excluded.~* Mood and anxiety disorders are permitted as long as compulsive hoarding is the primary diagnosis.~* Participants will are not eligible if they have active suicidal ideation, those participants will be given immediate medical or mental health attention.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Cognitive Rehabilitation (Type: EXPERIMENTAL): Cognitive rehabilitation and exposure therapy for hoarding
- Arm 2: Case Management (Type: ACTIVE_COMPARATOR): Case management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Anticipated need for intravenous antibiotic therapy of 5 days or longer.~* Patients known or suspected to have a complicated skin and skin structure infection. Complicated skin/skin structure infection includes infections either involving deeper soft tissue or requiring significant surgical intervention or a significant underlying disease state (such as diabetes mellitus, peripheral vascular disease, peripheral neuropathy, lower venous insufficiency) that complicates response to treatment.~Other inclusion applies~Exclusion Criteria:~* Patients with any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed.~* Patients with severely impaired arterial blood supply and insufficiency such that the likelihood of amputation of the infected anatomical site within one month is likely.~* Infected diabetic foot ulcers or decubitus ulcers where the infection is present for greater than one week's duration or chronically infected decubitus ulcers in patients who can not be compliant with measures necessary for chronic wound healing.~* Necrotizing fasciitis or gangrene.~Other exclusion applies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lamotrigine for Symptoms of Geriatric Bipolar Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 Years or older~* BP Disorder-I or II: Depressive episode (DSM -IV-TR; SCID-I/P)~* HAM-D score \> 18 (GRID-HAM-D 24-item version)~* Availability of an Informant is encouraged but not required for study participation~Exclusion Criteria:~* Chronic psychotic conditions, ie. schizophrenia, schizoaffective disorder, delusional disorder~* Contraindication to lamotrigine (Physician interview, medical assessment)~* Documented history of intolerance to lamotrigine~* Patients who have previously failed to respond to at least 12 weeks of treatment with lamotrigine~* Active substance dependence (SCID-I/P) or substance-related safety issues or PI concerns~* Mood Disorder Due to a General Medical Condition or Treatment (Physician interview)~* Rapid cycling (Physician interview): As defined in DSM-IV: At least 4 episodes of mood disturbance in the previous 12 months that meet criteria for a Major Depressive, Manic, Mixed or Hypomanic Episode. Episodes are distinguished either by partial or full remission for at least 2 months or by a switch to an episode of opposite polarity~* Dementia (by DSM-IV or brain degenerative diseases; Physician interview);~* Inability to communicate in English (i.e., interview cannot be conducted without an interpreter; subject largely unable to understand questions and cannot respond in English)~* Clinically significant sensory impairment (i.e., cannot see well enough to read consent or visually-presented material; cannot hear well enough to cooperate with interview; Physician interview)~* Recent history of cardiovascular, peripheral vascular events or stroke~* High risk for suicide (e.g., active SI or current intent or plan)~* Inpatient status

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label Lamotrigine Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DHA Supplementation and Pregnancy Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant 8-20 wks at enrollment~* single fetus~* BMI \<40~Exclusion Criteria:~* diabetes (Type I, ii, GDM)~* hypertension (primary, PIH, preeclampsia/eclampsia)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 36 Years
- Healthy Volunteers: t

Study Arms:
- DHA capsules (Type: EXPERIMENTAL): DHA capsules
- Placebo capsules (Type: PLACEBO_COMPARATOR): Placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients meeting the Rome III Diagnostic Criteria~* Loose (mushy) or watery stools within the last 3 months~* Abdominal discomfort and/or pain during their non-menstrual period~Exclusion Criteria:~* Patients with a history of surgical resection of the stomach, small intestine or large intestine~* Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)~* Patients with a history or current diagnosis of colitis ischemic~* Patients with a current diagnosis of enteritis infectious~* Patients with a current diagnosis of hyperthyroidism or hypothyroidism~* Patients who are currently participating in another clinical trial (including a post-marketing clinical study) or those who participated in another clinical trial (including a post-marketing clinical study) within 12 weeks before the study~* Patients with a history or current diagnosis of malignant tumor~* Patients with a history of abuse of drugs or alcohol within 1 year or those who are currently abusing them

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- placebo group (Type: PLACEBO_COMPARATOR): None
- YM060 low-dose group (Type: EXPERIMENTAL): None
- YM060 middle-dose group (Type: EXPERIMENTAL): None
- YM060 high-dose group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age equal to or above18 years at the time of signing informed consent~* Diagnosed with T2D at least 180 days prior to the day of screening~* HbA1c of 8-10% (64-86 mmol/mol) (both inclusive)~* Stable daily dose(s) for 90 days prior to the day of screening of:~* Any metformin formulations (equal to or above1500 mg or maximum tolerated or effective dose) alone or in combination with sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose)~Exclusion Criteria:~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes~* Renal impairment measured as estimated glomerular filtration rate (eGFR) value of \<30 mL/min/1.73 m\^2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) creatinine equation as defined by KDIGO 2012 classification~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 2.0 mg (Type: EXPERIMENTAL): All participants will receive one injection per week during a 12-week dose escalation period, until the target dose for semaglutide 2.0 mg is reached. From week 13 to week 40, semaglutide will be given in two weekly injections of 1.0 mg each.
- Semaglutide 1.0 mg (Type: ACTIVE_COMPARATOR): All participants will receive one injection per week during a 12-week dose escalation period. From week 13 to week 40, the 1.0 mg group will receive an additional injection of semaglutide placebo in order to maintain the blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant, non-lactating females who are 18 years or older~* Laboratory-proven acute Q fever since the year 2007 and/or positive serology fitting a past infection with Coxiella burnetii;~* AND being severely fatigued, defined by scoring 35 or higher on the subscale fatigue severity of the CIS;~* AND being fatigued for at least 6 months;~* AND disabled because of the fatigue, defined by scoring 450 or higher on the SIP~* Subjects must sign a written informed consent form.~Exclusion Criteria:~* Fulfilling criteria for chronic Q fever, namely:~  * IFA IgG fase I ≥ 1024, ≥ 3 months after acute Q fever and/or~ * Positive Coxiella burnetii PCR on serum or tissue, 1 month after acute Q fever~* Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or stenting necessitating prophylactic use of doxycycline;~* Pregnancy or unwillingness to use effective contraceptives during the entire study period;~* Imminent death;~* Inability to give informed consent;~* Allergy or intolerance to doxycycline;~* Somatic or psychiatric illness that could explain the chronic fatigue;~* Subjects who are currently enrolled on other investigational drug trials or receiving investigational agents;~* Receiving antibiotics for more than 4 weeks, potentially active against Coxiella burnetii, for any other reason since Q-fever diagnosis;~* Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or carbamazepine (these drugs may increase the metabolism of doxycycline and therefore reducing half-life of doxycycline);~* Moderate or severe liver disease (AF, ALAT, ASAT \> 3 times the upper limit of normal).~* Current engagement in a legal procedure concerning financial benefits (only current involvement interferes with the effectivity of cognitive behavioral therapy. Once the appeal procedure ends, subjects can be included)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive behavioral therapy (Type: EXPERIMENTAL): None
- Doxycycline (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follicular Steroid Genesis in Controlled Ovarian Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Good physical and psychological condition~* Normal menstrual cycle (25-35 days)~* Normal ovarian reserve defined by serum ANH010-30 pMol/L~* All other criteria to fulfill by oocyte donors~Exclusion Criteria:~* Kidney failure~* Ovarian Polyquistic syndrome~* Any systemic or metabolic disfunction that counter indicates the use of gonadotrophins~* Any other reason that involves exclusion of the oocyte donation program

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- rFSH (Type: ACTIVE_COMPARATOR): Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
- HP-HMG (Type: ACTIVE_COMPARATOR): Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete